Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 22,600 shares, an increase of 6.1% from the October 31st total of 21,300 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average trading volume of 30,300 shares, the days-to-cover ratio is presently 0.7 days.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Akari Therapeutics in a report on Tuesday, November 26th. They issued a “sell” rating for the company.

Akari Therapeutics Trading Up 12.4 %

NASDAQ AKTX opened at $1.36 on Tuesday. The business’s fifty day moving average is $2.31 and its 200 day moving average is $2.85. Akari Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.